G28-5
G28-5
规格:
货期:
编号:TS212147
品牌:Testobio
| 产品名称： | G28-5 |
|---|---|
| 商品货号： | TS212147 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain:xa0 BALB/c (B cell); BALB/c (myeloma) |
| Applications： | The antibody is specific for the Bp50 (CD40) B cell surface antigen. The antibody reacts specifically with CD20 positive (Bp35, B1) blood and tonsillar B cells, and does not react with T cells or NK cells. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against Bp50 (CD40, human B cell antigen) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against Bp50 (CD40, human B cell antigen) |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/c mice |
| Comments： | Animals were immunized with human tonsillar lymphocytes. Spleen cells were fused with NS-1 myeloma cells. The antibody is specific for the Bp50 (CD40) B cell surface antigen. The antibody reacts specifically with CD20 positive (Bp35, B1) blood and tonsillar B cells, and does not react with T cells or NK cells. It does react with malignant B cells and B cell lines. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by the addition of fresh medium or by replacement of medium. Alternatively, cultures can be established by centrifigugation with subsequent resuspension at 2 X 10(5) viable cells/ml. Maintain between 1 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: culture medium, 92.5%; DMSO, 7.5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG1 |
| Name of Depositor： | Oncogen |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Ledbetter JA, Clark EA. Ligands and methods for augmenting B-cell proliferation. US Patent 5,182,368 dated Jan 26 1993 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
G28-5
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | G28-5 |
|---|---|
| 商品货号： | TS212147 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain:xa0 BALB/c (B cell); BALB/c (myeloma) |
| Applications： | The antibody is specific for the Bp50 (CD40) B cell surface antigen. The antibody reacts specifically with CD20 positive (Bp35, B1) blood and tonsillar B cells, and does not react with T cells or NK cells. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against Bp50 (CD40, human B cell antigen) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against Bp50 (CD40, human B cell antigen) |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/c mice |
| Comments： | Animals were immunized with human tonsillar lymphocytes. Spleen cells were fused with NS-1 myeloma cells. The antibody is specific for the Bp50 (CD40) B cell surface antigen. The antibody reacts specifically with CD20 positive (Bp35, B1) blood and tonsillar B cells, and does not react with T cells or NK cells. It does react with malignant B cells and B cell lines. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by the addition of fresh medium or by replacement of medium. Alternatively, cultures can be established by centrifigugation with subsequent resuspension at 2 X 10(5) viable cells/ml. Maintain between 1 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: culture medium, 92.5%; DMSO, 7.5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG1 |
| Name of Depositor： | Oncogen |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Ledbetter JA, Clark EA. Ligands and methods for augmenting B-cell proliferation. US Patent 5,182,368 dated Jan 26 1993 |
